These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Completed, but no date, and reported results Terminated 2007-004866-42 An Open-label Randomized Phase II Study of Panitumumab Plus Oral Capecitabine and Infusional Oxaliplatin (XELOX) or XELOX alone for Second-line Treatment of Patients with Metastatic Clororectal Cancer... bad-data
Reported results Terminated 2008-000803-26 A controlled randomized double-blind multi-center phase II study of FOLFOX6 or FOLFIRI combined with sorafenib versus placebo in second-line metastatic colorectal carcinoma 2012-10-02 due-trials
Completed, but no date 2008-007798-18 An Open Label Randomized Controlled Phase II Trial of Panitumumab in Combination with Epirubicin, Cisplatin and Capecitabine (ECX) versus ECX Chemotherapy alone in Subjects with Locally Advanced Gastr... bad-data
Reported results 2008-007974-39 Randomized three arm phase III trial on induction treatment with a fluoropyrimidine-, oxaliplatin- and bevacizumab-based chemotherapy for 24 weeks followed by maintenance treatment with a fluoropyrimi... 2015-08-14 due-trials
Completed, but no date, and reported results Terminated 2009-014725-16 Double-blind, placebo-controlled, randomized phase II-study investigating the efficacy of Bevacizumab for symptom control in patients with malignant ascites due to advanced-stage gastrointestinal canc... bad-data
Not reported 2009-017731-17 An open-label 2:1 randomized phase II study of panitumumab plus FOLFOXIRI or FOLFOXIRI alone as first-line treatment of patients with non-resectable metastatic colorectal cancer and RAS wild-type 2022-01-20 due-trials
Reported results 2010-020606-15 An open-label, randomized phase III trial of cisplatin and 5-fluorouracil with or without panitumumab for patients with nonresectable, advanced or metastatic esophageal squamous cell cancer 2015-05-27 due-trials
Not reported 2010-022938-85 Comparison of two preemptive treatment strategies of panitumumab mediated skin toxicity and assessment of quality of life in patients with Ras-wildtype colorectal cancer 2016-03-01 due-trials
Completed, but no date, and reported results 2010-024111-13 Explorative trial to investigate catumaxomab (anti-EpCAM x anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric adenocarcinomas prior to gastrectomy bad-data
Reported results 2011-001024-38 Randomisierte Phase II Studie zum Vergleich der Therapie Vinorelbin in Kombination mit dem mTOR-Inhibitor Everolimus vs. Vinorelbin Monotherapie in der Zweitlinienbehandlung von Patientinnen mit metas... 2016-10-31 due-trials
Completed, but no date, and reported results 2011-001507-13 Multicenter, explorative phase II study of perioperative 5-FU, leucovorin, docetaxel, and oxaliplatin (FLOT) in combination with Trastuzumab in patients with HER2-positive, locally advanced resectable... bad-data
Completed, but no date, and reported results 2012-004550-28 EVINEC: Safety and Tolerability of Everolimus as second-line treatment in poorly differentiated neuroendocrine carcinoma / neuroendocrine carcinoma G3 according to WHO 2010 and neuroendocrine tumor G3... bad-data
Ongoing 2012-005422-30 Randomized Phase II study for evaluation of efficacy and safety of maintenance treatment with 5-FU/FA plus panitumumab vs. 5-FU/FA alone after prior induction treatment with mFOLFOX6 plus panitumumab ... not-yet-due
Listed as ongoing, but also has a completion date 2013-002742-37 Randomized controlled trial of S-1 maintenance therapy in metastatic esophagogastric cancer 2020-10-16 bad-data
Reported results 2013-004796-12 Prospective Randomized Multicenter Phase II Trial to Investigate Intensified Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer Prospektive, randomisierte Phase-II Studie zur intensivie... 2020-02-19 due-trials
Completed, but no date, and reported results Terminated 2013-005545-37 A Phase II Study of Cabazitaxel for Patients with Breast or Lung Cancer and Recurrent or Progressive Brain Metastases (CaBaMet) Phase II Studie zur Behandlung mit Cabazitaxel von Patienten mit rezi... bad-data
Completed, report not yet due 2013-005559-34 Neoadjuvant plus adjuvant or only adjuvant nab-Paclitaxel plus Gemcitabine for resectable pancreatic cancer - The AIO-NEONAX trial (AIO-PAK-0313) A prospective, randomized, controlled, phase II study ... 2022-10-21 not-yet-due
Completed, but no date, and reported results Terminated 2014-001983-36 Maintaining ERBB blockade in EGFR-mutated lung cancer (MARBLE) - A randomized, open-label, phase II study of maintaining pan-ERBB blockade following platinum-based induction chemotherapy in patients w... bad-data
Completed, but no date 2014-004086-24 Induction Treatment with nab-Paclitaxel/Gemcitabine for First-line Treatment of Metastatic Pancreatic Cancer Followed by Either Alternating Application of Gemcitabine Monotherapy and nab-Paclitaxel/Ge... bad-data
Reported results Terminated 2014-005595-28 Induction therapy with gefitinib followed by taxane platinum chemotherapy and intercalated gefitinib in NSCLC stages II-IIIB with activating EGFR mutation – A single arm Phase II trial. Einleitung... 2017-03-16 due-trials
Not reported 2015-001123-22 A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Pembrolizumab Maintenance Following First-Line Platinum Based Chemotherapy in Patients with Metastatic Squamous - Non-Small Cell Lung C... 2020-11-24 due-trials
Other 2015-001478-16 Rivaroxaban in the treatment of venous thrombembolism (VTE) in cancer patients – a randomized phase III Study Randomisierte Phase III Studie zum Stellenwert von Rivaroxaban zur Behandlung venöser T... not-yet-due
Completed, report not yet due 2015-002773-38 mFOLFOX6 vs. mFOLFOX6 + aflibercept as neoadjuvant treatment in MRI-defined T3-rectal cancer: a randomized phase-II-trial Kombinationschemotherapie mFOLFOX6 vs. Kombinationschemotherapie mFOLFOX6 +... 2022-06-01 not-yet-due
Reported results 2015-005741-31 Fostering efficacy of anti – PD-1 – treatment: Nivolumab plus radiotherapy in advanced NSCLC Förderung der Wirksamkeit einer anti-PD-1-Behandlung (Immuntherapie Nivolumab) in Kombination mit Stra... 2021-05-14 due-trials
Ongoing 2016-000399-28 A phase III study testing the role of PRoactivE coaching on PAtient REported outcome in advanced or metastatic renal cell carcinoma treated with sunitinib or a combination of pembrolizumab + axitinib ... not-yet-due
Reported results Terminated 2016-001331-12 A randomized phase II study comparing pembrolizumab with methotrexate in elderly, frail or cisplatin-ineligible patients with head and neck cancers 2021-12-03 due-trials
Reported results 2016-002170-13 A randomized phase II study with NIVOlumab or continuation of therapy as an early SWITCH approach in patients with advanced or metastatic renal cell carcinoma (RCC) and disease control after 3 months ... 2020-10-23 due-trials
Listed as ongoing, but also has a completion date 2016-002307-26 A phase II single arm clinical trial of a Tailored ImmunoTherapy Approach with Nivolumab in subjects with metastatic or advanced Renal Cell Carcinoma 2021-10-01 bad-data
Ongoing 2016-002467-34 Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary-tract cancer - An open label, non-comparative, randomized, multicenter phase II trial not-yet-due
Completed, report not yet due 2016-003709-33 A randomized phase II trial of nal-IRI and 5-Fluorouracil compared to 5-Fluorouracil in patients with cholangio- and gallbladder carcinoma previously treated with gemcitabine-based therapies 2022-03-08 not-yet-due
Ongoing 2016-003963-20 Durvalumab (MEDI4736) in frail and elder patients with metastatic NSCLC not-yet-due
Ongoing 2016-004434-26 Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer – The phase II AVETUX-CRC trial. Avelumab und Cetuximab in Kombination mit FOLFO... not-yet-due
Completed, report not yet due 2016-004750-15 A randomized phase II study of Durvalumab (MEDI4736) and Tremelimumab compared to doxorubicin in patients with advanced or metastatic soft tissue sarcoma. Eine randomisierte Phase-II-Studie mit Dur... 2022-08-12 not-yet-due
Ongoing 2016-004857-33 A phase II single arm clinical trial of a Tailored ImmunoTherapy Approach with Nivolumab in subjects with metastatic or advanced Transitional Cell Carcinoma Eine einarmige klinische Prüfung (Phase ... not-yet-due
Ongoing 2016-005147-17 Second-line therapy with Nal-IRI/5-FU/FA after failure of gemcitabine/nab-paclitaxel in advanced pancreatic cancer - predictive role of 1st-line therapy Zweitlinientherapie mit Nal-IRI/5-FU/FA nach... not-yet-due
Ongoing 2017-000105-20 Neoadjuvant anti PD-1 immunotherapy in resectable non-small cell lung cancer Neoadjuvante anti-PD-1 Immuntherapie bei operablem nichtkleinzelligen Lungenkrebs not-yet-due
Completed, report not yet due 2017-000624-10 Ipilimumab or FOLFOX in combination with Nivolumab and Trastuzumab in previously untreated HER2 positive locally advanced or metastastic EsophagoGastric Adenocarcinoma - The randomized phase 2 INTEGA ... 2022-03-05 not-yet-due
Completed, report not yet due 2017-001538-25 A randomized phase II trial of durvalumab and tremelimumab with gemcitabine or gemcitabine and cisplatin compared to gemcitabine and cisplatin in treatment-naïve patients with cholangio- and gallbladd... 2022-03-15 not-yet-due
Reported results 2017-002056-86 A multicenter open-label phase II trial to evaluate Nivolumab and Ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer Eine multizentrische offene Phase... 2021-11-20 due-trials
Reported results 2017-003349-14 A randomized phase II study on the optimization of immunotherapy in squamous carcinoma of the head and neck (OPTIM) Eine randomisierte Phase-II-Studie zur Optimierung der Immuntherapie bei Plattene... 2021-06-20 due-trials
Not reported 2017-003553-42 A Phase II single-arm, open-label study of transarterial chemoembolization (TACE) in combination with nivolumab performed for intermediate stage hepatocellular carcinoma (HCC) Eine offene, einarmig... 2021-12-10 due-trials
Ongoing 2017-003780-35 Randomized phase II, open-label efficacy and safety study of second-line durvalumab plus tremelimumab versus platinum-based chemotherapy alone in patients with NSCLC and first-line checkpoint-inhibito... not-yet-due
Ongoing 2019-001707-21 Single-Arm Phase II-Study in Patients with extensive stage small-cell lung cancer (ES-SCLC) with Poor Performance Status receiving Atezolizumab-Carboplatin-Etoposide Eine einarmige Phase-II-Studie ... not-yet-due
Not reported 2020-002605-25 Neoadjuvant Bintrafusp alfa in patients with resectable biliary tract cancer (NEOBIL) Neoadjuvante Therapie mit Bintrafusp alfa bei Patienten mit operablem Krebs der Gallenwege (NEOBIL) 2022-01-05 due-trials
Ongoing 2020-002715-21 Perioperative/Adjuvant atezolizumab with or without the immunomodulatory IMM-101 in patients with MSI-high or MMR-deficient stage III colorectal cancer ineligible for oxaliplatin-based chemotherapy– a... not-yet-due
Ongoing 2020-003512-27 Radiation during Osimertinib Treatment: a Safety and Efficacy Cohort Study not-yet-due
Ongoing 2020-005771-12 Neoadjuvant encorafenib, binimetinib and cetuximab for patients with BRAF V600E mutated/pMMR localized colorectal cancer not-yet-due